The European Committee for Medicinal Products for Human Use (CHMP) recommended 2 biosimilars for approval: Celltrion Healthcare’s bevacizumab candidate and Formycon’s prospective ranibizumab product.
The European Committee for Medicinal Products for Human Use (CHMP) gave positive opinions, essentially recommending for the European Commission to grant marketing authorization, for 2 biosimilar candidates: Celltrion Healthcare’s bevacizumab candidate (Vegzelma; CT-P16) and Formycon’s prospective ranibizumab product (FYB201).
Vegzelma references Avastin and, if approved, would be used in the treatment of several types of cancer, including metastatic breast cancer, non–small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer, and cervical cancer.
The positive opinion for the bevacizumab candidate is based on evidence from a phase 3 study that established comparable safety, efficacy, pharmacokinetic profiles between CT-P16 and the EU-approved version of Avastin in patients with metastatic or recurrent nonsquamous non–small cell lung cancer. In the study, CT-P16 was found to be well tolerated by patients and demonstrated biosimilarity between the biosimilar and reference product.
“If approved, Vegzelma (CT-P16) will be the third therapeutic oncology biosimilar in our biosimilar pipeline….Today’s positive CHMP opinion underscores Celltrion’s strong heritage in oncology and ongoing commitment to bringing high quality and innovative biosimilars to the market, providing additional treatment options for people living with cancers,” said Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, in a statement.
FYB201 is a biosimilar to Lucentis, which is used to treat patients with ophthalmic conditions, such as neovascular (or wet) age-related macular degeneration, macular edema, and diabetic retinopathy.
The CHMP recommended the biosimilar based on data from a randomized, double-blind, multicenter, parallel-group phase 3 study that established biosimilarity between FYB201 and Lucentis in patients with wet age-related macular degeneration.
Formycon has licensing agreements with Teva Pharmaceuticals and Bioeq, who will have the distribution rights for FYB201 in Europe and other territories upon approval.
If Vegzelma is granted marketing authorization, it will become 1 of 8 bevacizumab biosimilars approved for use in the European Union. Byooviz is currently the only ranibizumab biosimilar approved by the European Medicines Agency.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.